Investor Relations

Latest Financial Results

Q3 2020

Quarter Ended Sep 30, 2020

Latest Annual Report

Fiscal Year Ended Dec 31, 2019

View Annual Report

Stock Information

Company Overview

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company’s two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation of Dexmedetomidine in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents.

BioXcel Therapeutics Presentation

BioXcel Therapeutics Presentation

Download BioXcel Therapeutics Presentation


Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information


BioXcel Therapeutics, Inc.
555 Long Wharf Drive
12th Floor
New Haven, CT 06511
United States
T: 475-238-6837

Investor Relations

Solebury Trout
John Graziano
T: 1.646.378.2942

Transfer Agent

American Stock Transfer and Trust